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Background: CD8+ T cell responses, restricted by major histocompatibility complex (MHC) class I molecules, are
critical to controlling human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV)
replication. Previous studies have used MHC-matched siblings and monozygotic twins to evaluate genetic and
stochastic influences on HIV-specific T cell responses and viral evolution. Here we used a genetically restricted
population of Mauritian cynomolgus macaques (MCM) to characterize T cell responses within nine pairs of
MHC-matched animals.
Findings: In MHC-matched animals, there was considerable heterogeneity in the specificity and magnitude of T cell
responses detected via individual peptide gamma interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assays.
These findings were further supported by full proteome pooled peptide matrix ELISPOT data collected from this
cohort at 52 weeks post-infection. Interestingly, peptide regions that elicited dominant T cell responses were more
commonly shared between MHC-matched MCM than peptide regions that elicited non-dominant T cell responses.
Conclusions: Our findings suggest that, while some T cell responses mounted during chronic infection by
MHC-matched MCM are similar, the majority of responses are highly variable. Shared responses detected in this
study between MHC-matched MCM were directed against epitopes that had previously elicited relatively dominant
responses in MCM with the same MHC class I haplotype, suggesting that the factors that influence dominance may
influence the reproducibility of responses as well. This may be an important consideration for future T cell-based
vaccines aiming to consistently and reproducibly elicit protective T cell responses.
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Genome-wide association studies have implicated the
major histocompatibility complex (MHC) class I genes,
and by extension the CD8+ T cell responses they re-
strict, in modulating durable control of human immuno-
deficiency virus (HIV) [1]. The role of CD8+ T cells in
viral control has been confirmed in nonhuman primates
using simian immunodeficiency virus (SIV) [2,3]. Despite
the correlation between CD8+ T cell responses and* Correspondence: doconnor@primate.wisc.edu
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reproduction in any medium, provided the orHIV/SIV control, a clear understanding of what consti-
tutes an effective T cell response against these viruses re-
mains elusive [4]. This is further confounded by complex
host MHC genetics and interhost viral variability, which
complicate the process of differentiating between the in-
fluence of genetic and stochastic factors in immune re-
sponses and disease progression [5].
Researchers have studied HIV-infected MHC-identical
siblings and monozygotic twins to assess how genetic
and stochastic effects influence HIV-specific immune re-
sponses, finding that T cell responses mounted in acute
infection are strikingly similar, but diverge later in MHC-
identical individuals [6-8]. This divergence may be attrib-
uted to stochastic expansions of HIV-specific CD8+ Td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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study HIV in this context, however, are rare and limited to
single pairs of individuals, preventing further insights into
immune responses and viral evolution in identical host
MHC backgrounds.
SIV infection of non-human primates is a well-
established model of HIV infection, allowing researchers
to infect macaques with clonal, pathogenic virus and
study SIV-specific T cell responses in animals with par-
ticular MHC class I alleles [10]. Mauritian cynomolgus
macaques (MCM) are unique because of their limited
MHC genetic diversity when compared to humans and
other macaque populations. The MHC genetics of MCM
have been well defined and most of the MHC class I di-
versity can be accounted for by only seven haplotypes,
termed M1-M7 [11-13]. Similarly, the MHC class II diver-
sity of MCM is very limited [14]. This allows for MCM to
be matched for both their MHC class I and class II haplo-
type and provides the rare opportunity to study both CD4+
and CD8+ host T cell responses, against clonal SIV in
cohorts of MHC-matched individuals.
In this study, we used 822 overlapping 15-mers span-
ning the entire SIVmac239 proteome to measure T cell
responses by gamma interferon (IFN-γ) enzyme-linked
immunospot (ELISPOT) in groups of MHC class I and
class II-matched animals. We hypothesized that animals
who shared identical MHC genes would mount T cell re-
sponses with similar peptide specificity and magnitude
at matching time-points, i.e. that responses in MHC-
matched animals are “reproducible”. Our use of MCM
allowed us to closely compare chronic T cell response
reproducibility among genetically similar animals.
We used 18 MCM homozygous or heterozygous for
the M1 or M3 MHC class I haplotype (6 M1/M1, 6 M1/
M3, and 6 M3/M3) in an individual 15-mer peptide
IFN-γ ELISPOT assay. Animals matched for their MHC
class I haplotype also were matched for their class II
haplotype. Animals were split into three groups, each
containing an M1/M1 pair, an M1/M3 pair, and an M3/
M3 pair, for a total of six animals per group. Each groupFigure 1 MHC-matched animals pairs. A total of 18 MCM evenly split be
using an individual peptide IFN-γ ELISPOT assay between 37 and 41 WPI. A
third of the SIVmac239 proteome. In each group, 2 MCM of each haplotypwas screened for responses against one third of the SIV-
mac239 proteome. Thus, each peptide was tested in
three pairs of animals between 37 and 41 weeks post-
infection (WPI) (Figure 1). ELISPOT assays were per-
formed as previously described [12,15,16] and positive
responses were defined as being greater than 75 spot-
forming cells (SFC) per million peripheral blood mono-
nuclear cells (PBMC) above background. One M1/M1
MCM pair, cy0321 and cy0322, screened against the Gag
and Nef proteins was excluded from comparisons due to
high background IFN-γ secretion in cy0322, over 100
SFCs, averaging 360 SFCs in the negative control wells.
The average background across the entire group was
24.3 SFCs with a range from 0 to 361 SFCs; however,
when we excluded cy0322, the average background was
5.2 SFCs and ranged from 0 to 16 SFCs. No responses
were detected in the three MCM pairs screened against
the Pol protein (data not shown); thus, comparisons
could not be made within these pairs.
Surprisingly, ELISPOT assays revealed a lack of con-
cordance in IFN-γ-producing T cell responses between
MHC-matched individuals screened against the same
proteins. None of the 5 MHC-matched pairs that could be
compared exhibited identical T cell specificity or magni-
tude against SIVmac239 (Figure 2). Indeed, the M1/M1
pair shared only 1 of 6 distinct responses (#7 in Figure 2),
while M1/M3 pairs shared 2 of 12 distinct responses (#16
and #17 in Figure 2), and M3/M3 pairs shared 3 of 10 dis-
tinct responses (#23, #28, and #31 in Figure 2). Three of
six shared responses were directed against previously de-
fined epitopes: Nef 196–203 HW8, Gag 146–154 HL9, and
Env 338–346 RF9 [5,11]. The remaining three shared re-
sponses were directed against Env 357–371, Nef 253–263,
and Nef 165–179 (Figure 2). No correlation in response
magnitude between animals was observed for shared re-
sponses (R2 = 0.197, P = 0.3782).
We next expanded our analysis, examining previously
collected 52 WPI full proteome matrix ELISPOT data
from this cohort [5]. This allowed for the comparison of
chronic T cell response reproducibility in larger groupstween the M1/M1, M1/M3, and M3/M3 haplotypes were screened
nimals were divided into 3 groups of 6 MCM and screened against a
e were represented.
Figure 2 SIVmac239-specific T cell responses detected by individual IFN- γ ELISPOT assays. Comparison of the location and magnitude of
SIVmac239-specific T cell responses detected by individual peptide IFN-γ ELISPOT assays from 18 MCM with the M1/M1, M1/M3, or M3/M3
haplotype. Animals were divided into pairs by MHC class I haplotype and each pair was screened against approximately one third of the SIV
proteome. Responses against the most immunogenic peptides within amino acid regions that elicited a response are shown and responses are
numbered for reference in Figure 2. Because no responses were detected by ELISPOT in group 3 animals screened against the Pol protein, these
animals are not shown. Due to high background IFN-γ secretion by cy0322, the M1/M1 Group 1 pair of cy0321 and cy0322 (asterisk) was not
included in our comparison of responses detected by ELISPOT; however, responses mounted by cy0321 are shown.
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Figure 3 52 WPI SIVmac239-specific T cell response reproducibility in MHC-matched MCM. On the x-axis are regions targeted by IFN-γ-
secreting T cells in at least one animal of that haplotype, as measured by 52 WPI pooled peptide matrix ELISPOT. On the y-axis is the proportion
of animals within that MHC-matched group that mounted a response to each region. In each group, six animals were compared, with the
exception of the M1/M1 group. Due to high background IFN-γ-secretion, cy0322 was excluded from comparison with other M1/M1 animals.
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Figure 4 Dominant and Non-dominant T Cell Response
Reproducibility. Of the 32 peptides that elicited a T cell response at
52 WPI within a given MHC-matched group, 22 induced a response
that was dominant in at least one animal within the same MHC class
I haplotype. The proportion of animals mounting a response against
these peptides was significantly greater than proportion of animals
within an MHC-matched group that mounted a response against a
peptide that did not elicit a dominant response in any animals with
that class I haplotype (P < 0.05). Responses were detected by full
proteome pooled peptide matrix ELISPOT at 52 WPI. Lines represent
the mean proportion of animals within an MHC-matched group
responding to target region and error bars represent the standard
error of the mean.
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proteome. Again, high non-specific IFN-γ secretion in
cy0322 prohibited detection of positive responses in this
animal. Animals were grouped by MHC haplotype and
for each region targeted by at least one animal, the pro-
portion of MHC-matched animals mounting a response
to that same region was calculated (Figure 3). None of the
responses mounted in any of the three MHC-matched
groups were detected in all of the animals screened, and
of the 32 regions targeted by T cells from at least one ani-
mal at 52 WPI, 20 were recognized by two or fewer
MHC-matched MCM (Figure 3). This further supports
our earlier observation of chronic-phase T cell response
discordance between MHC-matched MCM. Moreover,
these results were confirmed in the M3/M3 animals that
had similar disease progression and viral loads, thus, elim-
inating potential confounding effects of some animals
controlling viral replication.
The availability of chronic-phase ELISPOT data from
both individual peptide ELISPOT assays and pooled pep-
tide matrix ELISPOT assays in the same cohort of ani-
mals provides an opportunity to assess the concordance
and sensitivity of these two assays. For each animal, only
the responses mounted within the proteins screened in
the individual peptide assays were compared. Of the 38
responses detected in individual peptide ELISPOT, 21
(55.3%) were again detected in the same animal at 52
WPI via matrix ELISPOT. Nine responses, however,
were detected by matrix ELISPOT that were not ob-
served in our individual peptide ELISPOT assays. This
suggests that the variability in responses detected may
be a product of differences in sampling time point, ra-
ther than a difference in assay sensitivity.
The discordance in chronic T cell responses made by
MHC-matched MCM was an intriguing finding, and one
that we explored further. Full proteome matrix ELISPOT
data from this cohort has allowed for the relative domin-
ance of each response detected in our individual peptide
ELISPOT assays to be examined. Here, we defined dom-
inant responses as constituting 25 percent or more of
the overall magnitude of the SIV-specific T cell response
in an animal at 24 or 52 WPI, as detected by matrix
ELISPOT. Interestingly, all six of the shared responses
identified by individual peptide ELISPOT were dominant
in at least one animal of the same haplotype, while only
nine of the 22 non-shared responses were dominant in
at least one animal of the same haplotype (Additional
File 1: Table S1).
When comparing more animals at 52 WPI across the
entire SIVmac239 proteome, we saw a similar pattern of
T cell response reproducibility. Peptides that elicited a
dominant response in at least one animal within an
MHC-matched group were significantly more likely to
elicit a T cell response in the other animals of that groupthan peptides that did not elicit a dominant response in
any animals within an MHC-matched group (P < 0.05,
Figure 4). This finding further supports earlier observa-
tions derived from individual peptide ELISPOT assays and
suggests that dominant responses may be more reprodu-
cible in chronic-phase SIVmac239 infection of MCM.
This study is, to our knowledge, the first to use MHC-
matched animals to screen all known SIVmac239 proteins
using only individual 15-mer peptides and to closely com-
pare the chronic-phase T cell responses mounted by
MHC-matched animals. ELISPOT revealed that, while
some responses from MHC-matched animals were shared,
the majority of IFN-γ secreting T cell responses were not
consistently detected between animals during chronic SIV
infection, and the magnitude of shared responses varied
considerably. These findings are consistent with research
on HIV-infected monozygotic twins and MHC-matched
siblings [6-8].
Dominant responses detected by ELISPOT were the
exception to this variability. This is consistent with the
highly reproducible immunodominant T cell response
hierarchies of inbred mice to pathogens such as influ-
enza A, lymphocytic choriomeningitis virus, and vaccinia
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nodominant HIV-specific response reproducibility in
humans [17-19]. Given the findings of our study, it is
plausible that factors such as antigen processing and
presentation, antigen-MHC class I binding affinity, T cell
avidity for the MHC class I-peptide complex, and naïve T
cell precursor frequency which contribute to the immuno-
dominance of certain CD8+ T cell responses [20] may also
contribute strongly to their reproducibility in MHC-
matched MCM. This may provide insight into ways in
which responses against subdominant epitopes, which
have been implicated in the control of HIV/SIV [2,21],
may be more reliably elicited. Despite the variability of
subdominant responses in MCM, it has been shown in
other models that immunodominance hierarchies can be
altered to favor effective responses against subdominant
epitopes [22] and further research in this area may inform
the design of HIV vaccines capable of reliably inducing a
variety of specific protective T cell responses in MHC-
diverse populations.
Additional file
Additional file 1: Table S1. Regions of the SIVmac239 proteome that
elicited T cell responses. Regions of the SIVmac239 proteome that elicited
T cell responses in our cohort and the individual peptide within each
region that induced the strongest response. Responses were detected via
individual peptide IFN-γ ELISPOT. The magnitude of the response against
the most immunogenic peptide is shown and responses are numbered
for reference in Figure 1 and Figure 2. Responses in bold italics are ones
that have been defined as dominant.
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